Laura Fawcett

Jan 14, 2024 | mja.com.au | Michelle S Lorentzos |David Metz |Andrew Moore |Laura Fawcett

Med J Aust || doi: 10.5694/mja2.52191 Published online: 15 January 2024 Opportunities for children to benefit from novel therapies have increased substantially over the past decade. Change is needed to maximise these opportunities, particularly in the paediatric trial environment. Investment and a coordinated national approach are needed to prevent Australian children falling behind their international peers.